IOLCP Q2 FY27 Revenue Surges 40.1% to ₹795 Crore, PAT Jumps 116.8%
IOL Chemicals and Pharmaceuticals Ltd. reported Q2 FY27 results with revenue up 40.1% to ₹795 crore and PAT up 116.8% to ₹65 crore. EBITDA increased 79.6% to ₹114.9 crore. The non-Ibuprofen pharmaceutical portfolio grew 70% YoY. The company plans forward integration into CDMO and formulation manufacturing.
The significant increase in financial metrics like revenue, EBITDA, and PAT, along with positive commentary on business performance and strategic direction, is expected to have a material positive impact on investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, exceeding previous periods and demonstrating improved margins. The management commentary highlights positive business drivers and strategic future plans.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its Unaudited Financial Results for the quarter and half year ended 30th September 2026. The company reported its highest-ever quarterly revenue, EBITDA, and PAT.
For the second quarter of FY27, IOLCP recorded a consolidated revenue from operations of ₹795.0 crore, a significant increase of 40.1% compared to ₹567.5 crore in Q2 FY26. EBITDA grew by 79.6% year-on-year to ₹114.9 crore, with the EBITDA margin expanding by 321 basis points to 14.4%. Profit After Tax (PAT) more than doubled, surging by 116.8% to ₹65.0 crore from ₹30.0 crore in the same period last year. The PAT margin also improved substantially by 290 basis points to 8.1%.
In the first half of FY27, revenue from operations stood at ₹1551.3 crore, up 38.6% from ₹1119.2 crore in H1 FY26. EBITDA for H1 FY27 was ₹226.6 crore, a 69.7% increase, and PAT was ₹129.5 crore, a 102.5% rise over H1 FY26. The EBITDA margin for H1 FY27 was 14.5%, and the PAT margin was 8.3%.
Mr. Vikas Gupta, Joint Managing Director, commented that the performance was driven by healthy demand across key products and improved operational efficiencies. The company's diversified business model and better product mix contributed to the margin expansion. The Pharmaceuticals business saw strong demand, with its non-Ibuprofen portfolio growing approximately 70% year-on-year and constituting 45% of pharmaceutical revenue. The Chemicals business also showed significant improvement, with its EBIT contribution increasing to about 7% from 1% year-on-year.
Looking ahead, IOLCP plans to leverage its manufacturing capabilities for forward integration into CDMO and formulation manufacturing to expand its offerings and strengthen customer relationships. The company's priorities include portfolio diversification, operational excellence, and expanding its presence in higher-value manufacturing.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.